Criteria for selection and application of molecular markers for clinical studies of osteoarthritis

Osteoarthritis and Cartilage

Volumn 11, Issue 3, 2003, Pages 153-158

  Otterness, Ivan G ^a   Swindell, A C ^a  

^a NONE   (United States)

Author keywords

Molecular markers; Selection criteria

Indexed keywords

MOLECULAR MARKER;

ARTICLE; BODY MASS; CLINICAL STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; HUMAN; OSTEOARTHRITIS; PATIENT MONITORING; POPULATION DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; STATISTICAL DISTRIBUTION; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0037347224     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1063-4584(02)00350-3     Document Type: Article

References (27)

1. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-40.
2. Lequesne MG, Mery C, Samson M, Gerard P. Indexes of severity for osteoarthritis of the hip and knee. Validation-value in comparison with other assessment tests. Scand J Rheumatol (Suppl) 1987;65:85-9.
3. Lohmander LS, Felson DT. Defining the role of molecular markers to monitor disease, intervention, and cartilage breakdown in osteoarthritis. J Rheumatol 1997;24:782-5.
4. Otterness IG, Saltarelli MJ. Using molecular markers to monitor osteoarthritis. In: Tsokos GC, Moreland LW, Kammer GM, Pelletier J-P, Martel-Pelletier J, Gay S, Eds. Modern Therapeutics in Rheumatic Disease. Totowa, NJ: Humana Press 2001;215-36.
5. Brandt KD. A pessimistic view of serologic markers for diagnosis and management of osteoarthritis. Biochemical, immunologic and clinicopathologic barriers. J Rheumatol 1989;39-42.
6. Poole AR. NIH white paper: biomarkers, the osteoarthritis initiative. A basis for discussion (2000): http://www.niams.nih.gov/ne/oi/oabiomarwhipap.htm.
7. Lohmander LS, Poole AR. Defining and validating the clinical role of molecular markers in osteoarthritis. In: Brandt KD, Lohmander LS, Doherty M, Eds. Osteoarthritis 2nd edn. Oxford: Oxford University Press 2002.
8. Garnero P, Rousseau JC, Delmas PD. Molecular basis and clinical use of biochemical markers of bone, cartilage, and synovium in joint diseases. Arthritis Rheum 2000;43:953-68.
9. Thonar EJ-MA, Manicourt D-H. Noninvasive markers in osteoarthritis. In: Moskowitz RW, Goldberg VM, Howell DS, Altman RD, Buckwalter JA, Eds. Osteoarthritis: Diagnosis and Medical/Surgical Management 3rd edn. Philadelphia, PA: Harcourt 2001;293-313.
10. Guidelines for Industry: Bioanalytical Method Validation. Bethesda, MD: U.S. Department of Health and Human Services, Food and Drug Administration 2001.
11. Findlay JWA, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, et al. Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 2000;21:1249-73.
12. Otterness IG, Swindell AC, Zimmerer RO, Poole AR, Ionescu M, Weiner E. An analysis of 14 molecular markers for monitoring osteoarthritis: segregation of the markers into clusters and distinguishing osteoarthritis at baseline. Osteoarthritis Cartilage 2000;8:180-5.
13. Otterness IG, Weiner E, Swindell AC, Zimmerer RO, Ionescu M, Poole AR. An analysis of 14 molecular markers for monitoring osteoarthritis. Relationship of the markers to clinical endpoints. Osteoarthritis Cartilage 2001;9:224-31.
14. Downs JT, Lane CL, Nestor NB, McLellan TJ, Kelly MA, Karam GA, et al. Analysis of collagen cleavage by collagenase using a neoepitope ELISA. Matrix Biol 2000;237:25-34.
15. Shapiro SS, Wilk MB, Chen HJ. A comparative study of various tests of normality. J Am Stat Assoc 1968;63:1343-72.
16. The marker might still have use if it is elevated during a specific disease stage and so could be used to define the disease stage in longitudinal studies.
17. Ting N. Chow S-C, Ed. Encyclopedia of Biopharmaceutical Statistics. New York, NY: Marcel Dekker 2000pp. 177.
18. Lohmander LS, Dahlberg L, Eyre D, Lark M, Thonar EJ, Ryd L. Longitudinal and cross-sectional variability in markers of joint metabolism in patients with knee pain and articular cartilage abnormalities. Osteoarthritis Cartilage 1998;6:351-61.
19. 2.
20. Otterness IG, Vázquez-Abad D. Clinical evaluation of molecular markers for osteoarthritis. In: Kuettner K, Haskell V, Reddi H, Eds. The Many Faces of Osteoarthritis. Birkhauser Verlag: Basel 2002 pp. 297-302.
21. Billinghurst RC, O'Brien K, Poole AR, McIlwraith CW. Inhibition of articular cartilage degradation in culture by a novel nonpeptidic matrix metalloproteinase inhibitor. Ann N Y Acad Sci 1999;878:594-7.
22. Atley LM, Sharma L, Clemens JD, Shaffer K, Pietka TA, Riggins HA, et al. The Collagen II CTx Degradation Marker is Generated by Collgaenase 3 and in Urine Reflects Disease Burden in Knee OA Patients (Abstract). Proceedings of Orthopedics Research Association, 46th Meeting, 2000, 0168.
23. Christgau S, Garnero P, Fledelius C, Moniz M, Ensig M, Gineyts E, et al. Collagen type II C-teleopeptide fragments as an index of cartilage degradation. Bone 2001;29:209-25.
24. Lohmander LS. What is the current status of biochemical markers in the diagnosis, prognosis and monitoring of osteoarthritis? Baillieres Clin Rheumatol 1997;11:711-26.
25. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, et al. Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 2002;46:2613-24.
26. Clark AG, Jordan JM, Vilim V, Renner JB, Dragomir AD, Luta G, et al. Serum cartilage oligomeric matrix protein reflects osteoarthritis presence and severity: the Johnston County Osteoarthritis Project. Arthritis Rheum 1999;42:2356-64.
27. The Z-score is a measure of the deviation of a value from the mean in units normalized to the standard deviation. A Z-score of -1 indicates the value is one standard deviation below the mean.